The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...
TECFIDERA is an oral therapy for relapsing forms of MS, including relapsing-remitting MS, the most common form of MS. In clinical trials, the most common adverse events associated with TECFIDERA were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results